CD19 Occupancy with Tafasitamab Increases Therapeutic Index of CART19 Cell Therapy and Diminishes Severity of CRS

Scientists evaluated the potential interference between the CD19-targeting monoclonal antibody tafasitamab and CART19 treatment in preclinical models.